Immunization with the receptor–binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
Jinkai Zang(The Ohio State University), Zhong Huang(Shenzhen University), Zhiping Sun(Shanghai Medical College of Fudan University), Bingjie Zhou, Shiqi Xu(Institut Pasteur of Shanghai), Dimitri Lavillette(Soochow University), Yang Wu(Wuhan University), Lulu Bai(Inner Mongolia Normal University), Zhenghong Yuan(Shanghai Medical College of Fudan University), Chao Zhang(Fudan University), Yong Yang(Institut Pasteur of Shanghai), Youhua Xie(Shanghai Medical College of Fudan University), Chenjian Gu(Washington University in St. Louis), Xueyang Zhang(Tsinghua University), Rong Zhang(Guangxi University), Hong Tang(Sichuan Agricultural University), Yu Zhou(Yangtze University), Di Qu(Xijing Hospital), Qiang Deng(Kunming University of Science and Technology)
Cited by 14
Related Papers
Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus
|New England Journal of Medicine|2013|2.4k
1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study
|The Lancet|2021|1.1k
Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study
|The Lancet Respiratory Medicine|2022|609
Etiological and epidemiological features of acute respiratory infections in China
|Nature Communications|2021|530